Allergy

The approval expands the current sublingual tablet treatment indications to include children with a ragweed pollen allergy.

The approval of the sBLA means greater flexibility and reduced barriers in care during the pandemic.

fMRI imaging shows decreased functional connectivity within the frontoparietal network of affected patients.

ClearUp Sinus Pain Relief treatment was previously approved for allergy-related sinus and nasal congestion and allergy-related sinus pain.

Guidelines reflect updated guidance from the CDC and FDA.

Consideration of how immunotherapy may influence other allergic diseases, patient adherence options, and advancing assessment of peanut allergy options.

Younger patients are faring better, and for longer, with sublingual immunotherapy. A leading investigator discusses what more needs to be learned in the burgeoning field.

From interpreting currently-understood risks to managing isolation-induced indoor allergen exposure, asthmatics may have concerns they address with clinicians.

How dupilumab is observed to benefit EoE patients—and who may administer the biologic therapy.

In data presented during AAAAI 21, researchers compared the 2006 and 2016 versions of the diagnostic criteria proposed by the NIAD/FAAN.

Perspective on how the interleukin-targeting biologic has unique benefit for the rare, under-resourced disease.

Late-breaking data show allegic children as young as 1-4 years old may have sustained benefit from daily peanut protein exposure.

The adjusted allergy prevalence in recent years was 2.6% in infants who have been introduced to peanuts at 12 months.

Common positive effects includes help with sleep, less pain, and calming influence.

A discussion on continued research into the first regulated treatment for pediatric peanut allergy.

Pending FDA decision, the Viaskin Peanut patch would be considered for lengthier benefit studies.

The epicutaneous immunotherapy for peanut allergy is continuing discussions with the FDA. What is its potential in allergic care?

In the initial report, investigators find just 2.5 cases of anaphylaxis per million doses of the Moderna COVID-19 vaccine.

An individualized model that provides vaccine-hesitant patients resources without compromising autonomy could aid efforts to limit the pandemic with new vaccines.

A conversation on how associations between the chronic conditions have become better understood in 10 years.

A discussion around obesity's effect on asthma, and the newest recommendations for managed care.

In nearly 1.9 million doses of the COVID-19 vaccine there has been only 21 total cases of anaphylaxis.

New research adds to the case that some children are genetically more susceptible to allergic disease.

Preschool children with asthma, food allergies, and pollen/fur or dust mite allergies are at increased risk of having concurrent mental health problems.

GalSafe pigs may potentially be used as a source of medical products, free of detectable alpha-gal sugar.